MedTrace Logo

Ozone Therapy After Open Flap Debridement in Periodontitis

NCT07551297 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2026-04-24

No results posted yet for this study

Summary

Periodontitis is a chronic inflammatory disease characterized by the destruction of supporting periodontal tissues. Open flap debridement (OFD) is a commonly used surgical approach for the treatment of deep periodontal pockets when non-surgical therapy is insufficient. However, complete elimination of pathogenic microorganisms remains challenging.

Ozone therapy has been proposed as an adjunctive treatment due to its antimicrobial, anti-inflammatory, and wound healing properties. This randomized split-mouth clinical trial aims to evaluate the clinical effectiveness of adjunctive ozone therapy in patients with Stage III periodontitis undergoing OFD.

A total of 24 systemically healthy patients diagnosed with Stage III periodontitis were included in the study. In each patient, one side was randomly assigned to receive OFD combined with ozone therapy (test group), while the contralateral side received OFD alone (control group).

Clinical periodontal parameters, including plaque index (PI), gingival index (GI), bleeding on probing (BOP), probing pocket depth (PPD), and clinical attachment level (CAL), were recorded at baseline and at 6 and 12 months after treatment.

The study aims to determine whether adjunctive ozone therapy improves clinical outcomes compared to conventional OFD alone.

Conditions

  • Periodontitis
  • Stage III Periodontitis

Interventions

PROCEDURE

Open Flap Debridement

Open flap debridement was performed to gain access to root surfaces for removal of subgingival plaque and calculus in sites with periodontal pockets.

DEVICE

Ozone Therapy

Adjunctive ozone therapy was applied to the test sites following open flap debridement using an ozone delivery device according to the manufacturer's instructions.

Sponsors & Collaborators

  • Alparslan Dilsiz

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-01
Primary Completion
2026-01-25
Completion
2026-02-18

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07551297 on ClinicalTrials.gov